- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
The Debate About Ending Interchangeability Designation for Biosimilars | Asembia 2024
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.
Lockhart spoke about biosimilars at an Asembia 2024 session yesterday but was interviewed earlier this month by Managed Healthcare Executive.
"The interchangeability, there's no scientific basis for that," Lockhart said in the interview. "They're already biosimilar so they've been shown to have no clinically meaningful difference. A clinical trial to demonstrate that something is not different is way too blunt of an instrument."
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
